Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Retroviruses as vectors

R G Vile1, S J Russell

  • 1Laboratory of Cancer Gene Therapy, Imperial Cancer Research Fund Rayne Institute, St Thomas' Hospital, London, UK.

British Medical Bulletin
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PIWIs, piRNAs and Retrotransposons: Complex battles during reprogramming in gametes and early embryos.

Reproduction in domestic animals = Zuchthygiene·2017
Same author

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.

Blood cancer journal·2017
Same author

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.

Leukemia·2017
Same author

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.

Leukemia·2017
Same author

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.

Blood cancer journal·2017
Same author

Natural history of t(11;14) multiple myeloma.

Leukemia·2017
Same journal

Human health in relation to visible, functional, and accessible green space: a systematic review and narrative synthesis of the 3 + 30 + 300 guideline.

British medical bulletin·2026
Same journal

Muscle herniae in exercise-induced leg pain: diagnostic pitfalls and the 'repair paradox'.

British medical bulletin·2026
Same journal

Scaffolds and platelet concentrates in bone regenerative medicine: applications, mechanisms, and future approaches.

British medical bulletin·2026
Same journal

Back squat and deadlift fatiguing protocols elicit distinct countermovement jump profiles: phase-specific predictors and soreness responses.

British medical bulletin·2026
Same journal

Enhancing bone healing through osteogenic medium components: biological roles, mechanisms, and clinical applications.

British medical bulletin·2026
Same journal

Moral injury in healthcare workers: causes & interventions.

British medical bulletin·2026
See all related articles

Retroviral vectors efficiently deliver genes into mammalian cells, integrating them into DNA for stable, long-term expression. Ongoing research focuses on improving these vectors for enhanced gene therapy applications.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biotechnology

Background:

  • Recombinant retroviruses are established tools for gene delivery to mammalian cells.
  • Widely available packaging cell lines and vector plasmids facilitate their use in research.
  • Retroviral vectors offer efficient gene transfer with no detectable cellular harm.

Purpose of the Study:

  • To review existing retroviral vectors.
  • To highlight current technological developments in retroviral vector systems.
  • To emphasize the ongoing need for improved retroviral vectors in gene therapy.

Main Methods:

  • Utilizing recombinant retroviruses for gene transfer.
  • Integrating retroviral nucleic acid into host chromosomal DNA.
  • Packaging up to 8 kilobases of foreign gene sequence.

Related Experiment Videos

Main Results:

  • Retroviral vectors demonstrate extraordinary efficiency in gene delivery.
  • Integrated retroviral DNA ensures stable, long-term gene expression and transmission.
  • Retroviral vectors are the preferred choice in 80% of approved clinical gene therapy trials.
  • No short- or long-term toxicity has been reported in human trials since 1989.

Conclusions:

  • Retroviral vectors are safe and effective for gene therapy.
  • Further development of retroviral vectors and packaging systems is crucial for advancing gene therapy.
  • Existing retroviral vectors provide a strong foundation for future innovations.